Articles Archive
Regeneron Posts Strong Q4 Earnings

Regeneron Posts Strong Q4 Earnings Feb. 2, 2024, 11:09 a.m., readers: 35

Regeneron Pharmaceuticals (NASDAQ:REGN) announced its fourth-quarter earnings, which exceeded expectations. For the fourth quarter, Regeneron reported an adjusted earnings per share (EPS) of $11.86, surpassing the consensus estimate of $10.62. The company's revenue for the quarter was $3.43 billion, exceeding analysts' expectations of $3.27 billion. Eylea net sales for the company amounted to $1.34 billion, which did not meet the anticipated $1.46 billion by Wall Street. However, Dupixent net sales were $2.49 billion, slightly exceeding the forecast of $2.47 billion.


R egeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization;

Price: 1037.08
Market cap: 112.4 billion USD
Eps: 33.86
P/e ratio: 30.63
Focus Analysis On: REGN
All news about: REGN